Sep. 12, 2013, 11:57 AM
- Amarin (AMRN -7.8%) slides after a U.S. appeals court reverses an earlier ruling on generic Lovaza, finding in favor of Teva (TEVA +1%) and Par Pharmaceuticals and against GlaxoSmithKline (GSK -0.3%) and Lovaza partner Pronova (PVNAF.PK).
- The ruling looks to clear the way for generic Lovaza.
- Both AMRN's Vascepa and Lovaza are indicated for the treatment of high levels of triglycerides.
- Full court ruling
There are no StockTalks on this stock yet.
PVNAF vs. ETF Alternatives
Other News & PR